• News Archive
  • Simaster
  • Webmail
  • Directory
  • Crisis Center
  •  English
    • Indonesia
Universitas Gadjah Mada Universitas Gadjah Mada Universitas Gadjah Mada Universitas Gadjah Mada
  • Education
    • Doctoral dissertation
    • Inauguration of Professor
    • Graduation
  • Achievement
  • Research and Innovation
    • Research
    • Innovation
  • Campus Info
    • Cooperation
    • Seminar and Workshop
    • Student Community Service Program
    • Other
  • News Report
  • Home
  • News Report
  • Virology Expert: Vaccine is Not One and Only Solution to Stop Covid-19

Virology Expert: Vaccine is Not One and Only Solution to Stop Covid-19

  • 18 August 2020, 10:41 WIB
  • By: Natasa Adelayanti
  • 2742
Pakar : Vaksin Bukanlah Solusi Hentikan Pandemi

At present, Indonesia is conducting clinical trials of the Sinovac vaccine from China. This trial was conducted on several volunteers as a phase of phase 3 clinical trials in Indonesia to evaluate the efficacy or reliability of the vaccine. Nevertheless, vaccines are not the only way to stop the Covid-19 pandemic, because previous coronavirus outbreaks such as SARS-CoV and MERS-CoV successfully stopped without vaccines.

This statement was stated by Mohamad Saifudin Hakim, MSc., Ph.D., as a virology expert from the UGM FKKMK, dr. on Monday (17/8), reacted to the phase three clinical trial of the Covid-19 vaccine, which is currently being examined in Indonesia. As his familiar name said, Hakim said that early coronavirus outbreaks such as the 2002-2003 SARS-CoV and 2012 MERS-CoV had successfully stopped without vaccines. Countries that have succeeded in holding back the rate of increase in Covid-19 cases, such as China itself, South Korea, New Zealand, and Taiwan, can suppress the rise in cases with well-executed and disciplined prevention efforts. "I reckon the government should make more various efforts to prevent the spread of Covid-19 optimally. However, there should be cooperation from the community to be disciplined in implementing efforts to prevent transmission. We have to really mean it," he said.

In his remarks, preventive measures such as case isolation, contact tracing and quarantine, physical imprisonment, using masks and washing hands, and community quarantine (lockdown) are urgently needed.

According to him, although the Sinovac vaccine product is currently being examined clinically, it cannot be claimed that this will be effective in the future, because it is necessary to wait for clinical trials. "Do not rush to conclude that the vaccine currently being clinically tested will be effective and be the choice for distribution. That is too early," he added.

He assessed that vaccine candidates that have entered the phase 3 clinical trial do not guarantee that the clinical trial will be successful. Many vaccine candidates have undergone phase 3 trials but failed because they proved to be ineffective.

However, Hakim argued that the Covid-19 vaccine's development is currently one of the efforts made by many countries to stop the pandemic. This condition is because many studies have shown that antibodies formed after SARS-CoV-2 infection naturally do not last long and disappear in 2-3 months.

Suppose later, the results of the Sinovac vaccine trial are successful in Indonesia. Indeed, it will be in the list of national immunization programs. According to him, the program's continuity will depend on sufficient vaccine supply. Therefore, he hopes that Indonesia can produce its own. "Sure, it will be easier to ascertain if we can produce our vaccines, compared to import products," he said.

According to him, PT. Biopharma is a party that has owned the technology for inactivated vaccines. However, the vaccine's mass production is still awaiting the results of this phase three clinical trial. "If this vaccine is proven to be effective and safe, then mass production can begin. Only then will the agreement between Sinovac, the Indonesian government, and PT. Biofarma, how many parts of the vaccine production will be produced by Biofarma," he said.

Author: Gusti Grehenson
Translator: Natasa A

 

Related News

  • UGM Expert: Community Still Must Adhere to Health Protocols After Vaccines Released

    Monday,19 October 2020 - 20:12
  • UGM Expert Pleads People to Stop Doubting the "Halal" Certification of the Sinovac Vaccine

    Tuesday,12 January 2021 - 17:57
  • UGM Expert Urges the Community not to Doubt the Vaccination

    Wednesday,13 January 2021 - 15:34
  • Myths vs. Facts of Covid-19

    Thursday,25 March 2021 - 10:25
  • UGM Expert: Preparation Tips before Getting Covid-19 Vaccine

    Friday,12 March 2021 - 20:41

News Releases

  • UGM Karate Unit Named 3rd Overall Champion of SEMAR CUP XII 31 March 2023
    UGM Karate INKAI Unit has won the 3rd Overall Cham
    Salma
  • Kabar UGM Named Gold Winner of 2023 SPS Awards 31 March 2023
    Universitas Gadjah Mada (UGM) has been presented w
    Salma
  • UGM Wins Most Social Media Awards at 2023 Public Relations Indonesia Awards (PRIA) 31 March 2023
    Universitas Gadjah Mada (UGM) has taken home multi
    Salma
  • UGM Students Win 2023 Chemical Engineering Car League (CIRCLE) 30 March 2023
    Reactics Chem-E-Car UGM has been crowned champion
    Salma
  • UGM to Build Moeso Suryowinoto Indonesia Biodiversity Center (MSIBC) 30 March 2023
    The UGM Faculty of Biology held a groundbreaking c
    Salma

Event

No latest event at this time

Universitas Gadjah Mada
UNIVERSITAS GADJAH MADA
Bulaksumur Yogyakarta 55281
   info@ugm.ac.id
   +62 (274) 588688
   +62 (274) 565223
   +62 811 2869 988

PARTNERSHIP

  • Alumni
  • International Affairs

ABOUT UGM

  • Rector's Welcome
  • History
  • Vission and Mission
  • The Board of Executive
  • Management

VISIT UGM

  • Campus Map
  • Event

REGISTRATION

  • Undergraduate
  • Graduate
  • Vocational School
  • Professional Program
  • International Program

© 2023 Universitas Gadjah Mada

PRIVACY POLICYCONTACT